Idiopathic pulmonary fibrosis (IPF) is a fatal respiratory disease characterized by excessive fibroblast activation ultimately leading to scarring of the lungs. Although, the activation of β 2 -adrenoceptors (β 2 -AR) has been shown to inhibit pro-fibrotic events primarily in cell lines, the role of β 2 -adrenoceptor agonists has not yet been fully characterized. The aim of our study was to explore the anti-fibrotic activity of the long-acting β 2 -adrenoceptor agonist olodaterol in primary human lung fibroblasts (HLF) and in murine models of pulmonary fibrosis.
Introduction
Idiopathic pulmonary fibrosis (IPF) is characterized by an irreversible decrease in oxygen diffusion capacity that is caused by a replacement of normal lung parenchyma by fibrotic scar tissue (Raghu et al., 2011) . Although the exact pathogenic processes and pathways underlying the initiation and progression of IPF are not yet fully understood, it is well known that the major player in the process of lung stiffening is the myofibroblast. Under fibrotic conditions, myofibroblasts differentiate from resident fibroblasts, which in turn exhibit higher proliferation rates. Myofibroblasts are characterized by the production of excess extracellular matrix (ECM) and by the expression of α-smooth muscle actin (α-SMA), which confers contractile properties on the cells. The recruitment of circulating mesenchymal precursor cells, namely, fibrocytes (Kuwana et al., 2003) , as well as epithelial cell trans-differentiation (Todd et al., 2012) may also provide a source of myofibroblasts. One of the main pro-fibrotic mediators, activating these cells and stimulating their differentiation towards ECM protein producing cells, is TGF-β (Desmouliere et al., 1993; Swigris and Brown, 2010) . Other prominent growth factors including PDGF-BB, FGF-2 and EGF stimulate the proliferation and recruitment of fibroblasts (Allen and Spiteri, 2002) . Further, the vasoconstrictor peptide endothelin-1 (ET-1) participates in the pathogenesis of pulmonary fibrosis (Shi-Wen et al., 2006; Swigris and Brown, 2010) .
Recently, the tyrosine kinase inhibitor nintedanib (Ofev®, Boehringer Ingelheim), targeting the receptors for PDGF (PDGFR), FGF (FGFR) and VEGF (VEGFR) (Hilberg et al., 2008; Richeldi et al., 2014) , and pirfenidone (Esbriet®, Roche), with known anti-fibrotic and antiinflammatory properties (Noble et al., 2011) , were shown to slow disease progression in patients with IPF, resulting in market authorization in many countries including the US and EU. While both drugs are able to significantly slow the pace of disease progression, for many patients, symptoms, like dyspnoea and cough, are still debilitating. Therefore, the need for additional treatment options is still high (Borie et al., 2016) .
Agonists at β 2 -adrenoceptors are well-established therapeutic options for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Upon agonist binding to the receptor, intracellular cAMP is synthesized. Besides their well-proven bronchodilatory properties, β 2 -adrenoceptor agonists, as well as other agents that increase cAMP levels, were shown to attenuate various pro-fibrotic mechanisms, such as proliferation or collagen and α-SMA expression, in cultured fibroblasts (Liu et al., 2004; Schiller et al., 2010; Lamyel et al., 2011) . Inhibition of PDEs was also shown to inhibit TGF-β-induced fibrotic events in fibroblasts (Dunkern et al., 2007) , and the PDE4 inhibitor roflumilast was shown to attenuate bleomycin-induced lung fibrosis in mice (Cortijo et al., 2009) . This indicates that cAMP elevating agents might also have therapeutic potential for the treatment of pulmonary fibrosis.
The primary aim of our study was to assess the ability of olodaterol (Striverdi®, Boehringer Ingelheim), an inhaled long-acting β 2 -adrenoceptor agonist approved for the oncedaily maintenance treatment of COPD (Bouyssou et al., 2010a; van Noord et al., 2011) , to inhibit pathogenic mechanisms involved in lung fibrosis. For this purpose, we performed different in vitro assays, including fibroblast proliferation and migration, myofibroblast differentiation and profibrotic mediator release using primary human lung cells from patients with IPF and control donors. To further confirm our data in the in vivo situation, we explored the activity of olodaterol in murine models of lung fibrosis.
Methods
All assays performed comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Culture conditions and assay set up
Normal human lung fibroblasts (HLF) (Lonza, Walkersville, MD, USA) from control donors and fibroblasts from donors with IPF (IPF-LF) (Asterand, Detroit, MI, USA) were grown in fibroblast basal medium (FBM) (CC-3131, Lonza Walkersville, Inc., Walkersville, MD, USA) supplemented with FGM-2 SingleQuot Kit Supplements & Growth Factors Lonza) . Cells were grown in a humidified incubator at 37°C and 5% CO 2 and passaged by trypsinization (ReagentPack Subculture Reagents, CC-5034, Lonza) at approximately 80% confluence. All assays were performed at passage 7 or 8.
For assay set-up, cells were seeded in fibroblast growth medium plus supplements in assay relevant densities. For all TGF-β-stimulated assays and the cAMP assay, cells were seeded at 4500 cells per well in 96-well plates. Proliferation assays were performed in 96-well plates at an initial seeding cell density on day 0 of 2000 cells per well. Cell motility assays were performed with 750 cells per well in 12-well plates. After 24 h, the cell culture medium was changed to starvation medium (FBM without supplements).
Compound treatment
After a 24 h starvation period, cells were pre-incubated for 30 min with different concentrations of olodaterol and subsequently stimulated with the assay relevant stimulus for the indicated time in the presence of the compound.
cAMP assay
Cells were stimulated with ICI-118,551 (30 nM), CGP-20712A (100 nM) or stimulation buffer (containing IBMX) at 37°C for 30 min. After antagonist pre-incubation, various olodaterol concentrations (1 pM to 1 μM in stimulation buffer) were added for another 30 min. cAMP release was determined with the cAMP-Glo ™ assay kit (Promega, Madison, WI, USA) according to the instruction manual.
α-SMA Western blot replacement assay 
Immunocytochemistry
For determination of collagen I assembly, the 'Scar-in-a-Jar' method was used as described elsewhere (Chen et al., 2009) 
Motility assay
Cells were stimulated with 20 ng·mL À1 PDGF-BB or FGFbasic. The motility of the cells was determined by time-lapse microscopy using a Cell-IQ® imaging system (Cenibra life science solution, Bramsche, Germany) and manual cell tracking performed with the Cell-IQ® analyser software. Cells were tracked continuously for approximately 72 h. Fifteen cells were analysed in each well, and the mean values of the cell movement velocity (pixel·h À1 ) were calculated for each well. In each experiment, three wells were sampled per condition.
Contraction assay
Collagen matrices in 48-well plates were prepared using 500 μL of a mixture containing 1.7 × 10 5 fibroblasts and 1 mg·mL À1 bovine type I collagen per well (PureCol®, Advanced BioMatrix, Carlsbad, CA, USA) in DMEM medium without serum. Polymerization of collagen matrices lasted for 60 min at 37°C. To initiate lattice contraction, FBM medium was added and freshly polymerized matrices were released from the underlying culture dish by using a spatula. The gels were then incubated at 37°C in a 5% CO 2 atmosphere and photographed after 24 h (starting area (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Ten-to twelve-week-old male C57BL/6 mice were obtained from Charles River Laboratories (Sulzfeld, Germany). Mice were fed standard chow diet and tap water ad libitum and housed under controlled temperature (22°C), under a 12 h light-dark cycle. The group size was calculated by a statistician and defined in the respective permit. A total of 110 mice were used in the experiments described here.
Bleomycin or AAV6.2m-TGF-β administration and olodaterol treatment. The models chosen, bleomycin challenge and TGF-ß overexpression in mice, have been used for several years to study lung fibrosis (Moore et al., 2013) . On day 0, mice were anesthetized with isoflurane (3-5%); either bleomycin (Calbiochem, Darmstadt, Germany) , at a dose of 0.5 mg·kg À1 (1.5-2 U·mg À1 ) in sterile isotonic saline (2 mL·kg À1 ), or adeno-associated virus (AAV) 6.2-TGF-β1, at a dose of 2.5 × 10 11 vg, was intratracheally instilled. The detailed method for the AAV6.2-TGF-β1 model is described elsewhere (Strobel et al., 2015) . Before starting treatment, the mice were randomly assigned to the different treatment groups. In a whole body exposure chamber, the animals were exposed to an aqueous solution of olodaterol aerosolized with a jet nebulizer (Pari Master; Pari GmbH, Starnberg, Germany) once daily for 5 min. To evaluate the efficacy of olodaterol, the compound was administered on either days 1-20 (preventive dosing) or days 7-20 (therapeutic dosing) after bleomycin or AAV6.2-TGF-β1 application.
Microcomputer tomography (μCT) of the lung. On day 21, lung density was assessed by μCT analysis. Animals were anesthetized with isoflurane (1.5%) and fixed in the prone position. μCT images were acquired with a Quantum FX μCT system (Perkin Elmer, Waltham, MA, USA) with cardiac gating (without respiratory gating), using the following parameters: 90 kV; 160 μA; FOV, 60 × 60 × 60 mm; spatial resolution, 0.11 mm. This resulted in a total acquisition time of 4.5 min. Images were analysed using MicroView 2.0 software (GE Healthcare, Amersham, UK). The Houndsfield unit (HU) corresponding to the peak of the HU-histogram for the segmented pixels was used as a measure of fibrosis.
After μCT analysis, animals were allowed to awaken from anaesthesia. Data were analysed using the flexiWare 7 software (SCIREQ).
Bronchoalveolar lavage fluid (BALF) and lung preparation. Animals were killed with an overdose of pentobarbital (800 mg·kg
À1
, i.p.), and lungs were lavaged twice with 0.8 mL lavage buffer (1× PBS + protease inhibitor cocktail; Roche, Mannheim, Germany). Total BALF cell counts and differential cell counts were quantified by means of a Sysmex XT1800 iVet cell analyser (Sysmex Europe GmbH, Norderstedt, Germany). After lavage, left lung lobes were fixed with 4% paraformaldehyde (PFA) (Boster, China) and inflated under 20 cm water pressure for 20 min. Right lung lobes were weighed and shock frozen in liquid nitrogen for further analyses.
Ashcroft scoring
PFA fixed lungs were embedded in paraffin following standard procedures. Lung sections (3 μm) were prepared and used for Masson's trichrome staining. Stained para-sagittal paraffin sections of the left lung lobe were systematically analysed in a microscope using a ×10 objective according to the scale defined by Ashcroft et al. (1988) . All samples were blinded prior to scoring.
Protein determination in BALF supernatant and lung homogenate
For the quantification of TGF-β, MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) Quantikine ELISAs from R&D Systems, Inc. (Minneapolis, MN, USA) were used. For the chemokine KC, TNF-α (both determined in BALF supernatant) and IL-1β (determined in lung homogenate), a mouse pro-inflammatory panel (MSD) was used. The bicinchoninic acid (BCA) assay was used to quantify total protein in cell-free BALF supernatant and lung homogenate. The BCA assay kit was purchased from Thermo Fisher Scientific (Waltham, MA, USA). A murine β 2 -adrenoceptor ELISA from Cusabio (Wuhan, China) was used to quantify levels of β 2 -adrenoceptors in lung homogenates.
Isolation of total RNA from mouse lungs
Frozen right lungs from the AAV-TGF-β model were homogenized in RLT buffer (Qiagen) plus 1% β-mercaptoethanol (Sigma-Aldrich) using the Omni Prep Multi-Sample Homogenizer (Omni International, Kennesaw, GA, USA). To isolate total RNA from formalin-fixed paraffin-embedded tissue slices in the bleomycin model, dewaxed 10 μm slices were incubated in PKD buffer plus Proteinase K (Qiagen) overnight at 56°C. Lung homogenate or tissue slice lysates were then mixed thoroughly with an equal volume of a phenol-chloroform-isoamyl-alcohol mixture (Sigma-Aldrich) and centrifuged in Phase Lock Gel Heavy 2 mL tubes (5Prime, Hamburg, Germany). The watery phase was then applied to the AllPrep DNA/RNA Mini Kit or the RNeasy FFPE kit (Qiagen), and RNA was purified according to the manufacturer's instructions.
TaqMan real-time PCR-analysis
Equal amounts of RNA of each sample were reversely transcribed to cDNA using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies, Carlsbad, CA, USA). qRT-PCR reactions were set up using the TaqMan® Fast Advanced Master Mix (Applied Biosystems, Carlsbad, CA, USA) and species-specific gene expression assays (Applied Biosystems: Hs00240532_s1, Hs00240532_s1, Mm00801666_g1, Mm01254476_m1, Mm00447142_m1). Gene expression analysis was performed with the ViiA7 ™ Real-Time PCR System and software (Applied Biosystems). Gene expression was normalized to the expression of RNA polymerase II (PolA2), which was used as housekeeping gene.
Data and statistical analysis
The data and statistical analysis in this study comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All data are presented as means ± SEM of n donors/animals. For the in vitro assays, technical replicates were used to ensure the reliability of single values. Unless otherwise noted, statistically significant differences between negative and positive controls were determined by an unpaired t-test for parametric data. The comparison of the test groups was determined by one-way ANOVA followed by Fisher's Least Significant Difference (LSD) test for parametric data. Statistical significance was accepted at P < 0.05. The tests were performed using GraphPad Prism version 7.00 for Windows, GraphPad Software, La Jolla, CA, USA, www.graphpad.com. To control for unwanted donor variances, the in vitro data were normalized as followed: the percentage inhibition was calculated according to the following: % inhibition = 100 À (Y/K1) * 100. K1 = mean rate of nonstimulated, non-compound-treated control wells subtracted from the mean rate of stimulated, non-compound-treated control wells. Y = mean rate of non-stimulated, non-compoundtreated control wells subtracted from the mean rate of stimulated, compound-treated wells. IC 50 values were calculated by nonlinear regression of log (inhibitor concentration) versus % inhibition using a three-or four-parameter fitting procedure of the Graph Pad Prism software package.
Materials
Olodaterol (BI 1744 CL) was synthesized at Boehringer Ingelheim (Biberach, Germany). ICI-118,551 hydrochloride and CGP-20712A methane sulfonate salt were obtained from Sigma-Aldrich (St. Louis, MO, USA). Human recombinant PDGF-BB, FGF-basic, EGF and TGF-β were purchased from R&D Systems, Inc. (Minneapolis, MN, USA). Human ET-1 was purchased from Biotrend (BIOTREND Chemikalien GmbH, Cologne, Germany). FBS was purchased from Gibco (Thermo Fisher Scientific, Waltham, MA, USA). All primary antibodies (anti-human phospho-PLCγ, phospho-SAPK/JNK, phospho-c-Raf, phospho-ERK1/2, phospho-Akt, phospho-p38, and GAPDH) used for the Western blot analysis were produced in rabbit and purchased from Cell Signaling Technology (Danvers, MA, USA). Peroxidase-conjugated mouse Anti-Rabbit IgG antibody was purchased from Jackson Immuno Research (West Grove, PA, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b,c) . 
Results

Olodaterol stimulates intracellular cAMP increase in primary human lung fibroblasts
To determine the expression of functional β 2 -adrenoceptors on control and diseased primary HLF, we stimulated cells with various concentrations of olodaterol in the presence or absence of 30 nM ICI-118,551 or 100 nM CGP-20712A, which, at the concentrations used, are selective β 2 -and β 1 -adrenoceptor antagonists, respectively (Chong et al., 2002) . Olodaterol increased levels of intracellular cAMP, in a concentration-dependent manner, in HLF and IPF-LF with EC 50 values of 740 and 690 pM, respectively. Pretreatment with ICI-118,551 caused a 201-fold EC 50 shift in HLF and a 106-fold shift in IPF-LF. Pre-incubation with CGP-20712A did not affect the olodaterol-induced cAMP increase in both cell types ( Figure 1A, B) . To further evaluate whether β 2 -adrenoceptor expression levels on HLF and IPF-LF correlate with the functional data, we measured β 2 -adrenoceptor expression in cell lysates using ELISA technique. Levels of the β 2 -adrenoceptor protein were comparable in HLF and IPF-LF ( Figure 1C ).
Figure 2
Olodaterol attenuates TGF-β-stimulated protein expression of primary HLF. Fibroblasts from control donors (HLF) and patients with IPF (IPF-LF) were pre-incubated with different concentrations of olodaterol and subsequently stimulated with TGF-β (4 ng·mL À1 ) for 48 h in the presence of the compound. α-SMA protein expression was measured in cell lysates by an MSD Western replacement assay (A). Pro-collagen I C-peptide (B), fibronectin (C) and ET-1 (D) expression was measured in supernatants by ELISA. Basal levels of 16 ng·mL À1 , 1.5 μg·mL À1 and 0.2 pg·mL Olodaterol attenuates TGF-β-induced fibroblast-to-myofibroblast transition
We next investigated the effects of olodaterol on TGF-β-stimulated myofibroblast differentiation. The TGF-β-induced increase in α-SMA protein expression in HLF and IPF-LF was significantly inhibited in a concentrationdependent manner by olodaterol with a maximal efficacy of 60% (HLF) and 42% (IPF-LF) at 10 nM (Figure 2A) . Furthermore, the expression of myofibroblast-specific mediators and ECM proteins like pro-collagen C-peptide (PICP) or fibronectin increased by approximately twofold in TGF-β-treated cells. Olodaterol concentration-dependently inhibited the PICP increase (from 20 to 40 ng·mL À1 ) with maximal efficacy of 70% at 10 nM ( Figure 2B ) in both HLF and IPF-LF. To visualize this effect, Figure 2E shows representative images of the TGF-β-induced collagen I assembly in HLF and the inhibitory effect of olodaterol. The increase of fibronectin release (from approximately 1.5 to 2.5 μg·mL À1 ) was inhibited by olodaterol by 65% at 1 nM ( Figure 2C ) for both cell types. Levels of the pro-fibrotic mediator ET-1 were hardly detectable in untreated cells and increased 40-and 60-fold in HLF and IPF-LF (5 and 6 pg·mL À1 , Figure 3 Olodaterol attenuates growth factor-induced motility and proliferation of primary HLF. The motility of fibroblasts from control donors (HLF) and patients with IPF (IPF-LF) after FGF or PDGF stimulation was measured by time-lapse microscopy and manual single cell tracking. respectively), after TGF-β-stimulation. Olodaterol blocked this mediator release with an IC 50 lower than 10 pM and a maximal inhibition of 100% and 50% at 1 nM, in HLFs and IPF-LF respectively ( Figure 2D ). To confirm that the inhibitory effects were driven by β 2 -adrenoceptors, the β 2 -adrenoceptor specific antagonist ICI-118,551 was tested in the ET-1 release assay. In the presence of ICI-118,551, olodaterol showed no inhibitory effects on TGF-β induced ET-1 release in HLF and IPF-LF ( Figure 2D ).
Olodaterol reduces FGF-and PDGF-induced cell motility of primary human lung fibroblasts
To assess the ability of olodaterol to attenuate FGF-and PDGF-induced migratory capacity of primary HLF, we performed migration assays using time-lapse microscopy. FGF and PDGF each induced approximately a twofold increase in cell motility. Olodaterol reduced the FGF-stimulated motility of HLF with an IC 50 value of 4 pM and a maximal efficacy of 75% at 100 pM. For IPF-LF, the inhibitory effect was not as marked and the maximal inhibition was reached at 10 nM ( Figure 3A) . With an IC 50 of 1 pM and a maximal efficacy of 80%, olodaterol inhibited PDGF-induced motility in HLF. In IPF-LF, the IC 50 shifted significantly to 34 pM and olodaterol reached a maximal inhibition of 50% at 10 nM ( Figure 3B ).
Olodaterol attenuates growth factor-and serum-induced proliferation of fibroblasts
Stimulation of cells with either EGF, FCS, FGF or PDGF induced fibroblast proliferation as assessed by BrdUincorporation. Pretreatment with olodaterol attenuated the growth factor-induced proliferation of fibroblasts. In HLF, the EGF-stimulated proliferation was maximally inhibited (by approximately 50%) at 100 pM and an IC 50 of 6 pM, while in IPF-LF with an IC 50 of 1.3 pM, the maximal inhibition was only 30% ( Figure 3C ). For FCS-induced proliferation, olodaterol only showed trends towards an inhibition ( Figure 3D ), whereas FGF-induced proliferation was potently attenuated in IPF-LF with an IC 50 of 10 pM and a maximal efficacy of 54% at 1 nM. Comparable values were measured for the inhibition in HLF ( Figure 3E ). At 100 pM, PDGF-induced proliferation was inhibited by 40% in HLF and was significantly different, only by 20%, in IPF-LF ( Figure 3F ).
Olodaterol prevents contraction of fibroblasts in collagen gels, induced by TGF-β plus ET-1
To study the effect of olodaterol in a functional bioassay, we used an in vitro floating collagen-gel contraction model. For this purpose, fibroblasts were embedded in type I collagen. The gel matrix was detached from the wells, and the contraction of the cell-gel matrix was stimulated with the pro-fibrotic stimuli TGF-β and ET-1. While each stimulus alone induced a contraction of the fibroblasts, which reduced the gel size by approximately twofold, the combination of both stimuli resulted in a threefold reduction in gel size. As shown in Figure 4A at 10 nM, olodaterol inhibited the contractile properties of HLFs by approximately 85%. On the contrary, for IPF-LF, the maximal inhibitory effect of olodaterol was 47% ( Figure 4A ). However, this numerical difference was not statistically significant.
Olodaterol inhibits FGF-induced phosphorylation of different fibrosis-relevant kinases
To identify molecular pathways where olodaterol might interfere with pro-fibrotic signalling, we stimulated fibroblasts with FGF for 5 min and checked the phosphorylation status of different fibrosis-relevant kinases (PLCγ, JNK, Raf-1, ERK1/2, Akt and p38 mitogen-activated protein kinase). All kinases showed an increased phosphorylation signal after 5 min of FGF stimulation compared with unstimulated cells (Figure 5 ). Table 1 shows the
Figure 4
Olodaterol attenuates contraction of primary HLF induced by TGF-β plus ET-1. Free-floating collagen lattices seeded with HLFs or IPF-LFs were treated with different concentrations of olodaterol in the presence of TGF-β (4 ng·mL À1 ), ET-1 (100 ng·mL À1 ) or a combination of both. Inhibition
of HLF or IPF-LF contraction by olodaterol (A). Photographs of a representative experiment (B)
. Surface area of collagen gels was calculated in % of starting area and expressed as normalized contraction (100% is defined as the contraction measured after treatment with TGF-β and ET-1). Data shown are means ± SEM of n = 5 donors of HLFs or IPF-LFs. Horizontal dotted line is 50% inhibition of the induced effect.
inhibitory effect of olodaterol on the FGF-induced phosphorylation of these kinases.
Olodaterol shows efficacy in a murine model of bleomycin-induced lung fibrosis, after preventive or therapeutic treatment
In order to address the inhibitory activity of olodaterol to attenuate the fibrotic pathology in vivo, we used a mouse model of lung fibrosis induced by bleomycin. Treatment with inhaled olodaterol (1 mg·mL À1 , q.d.) was either started at day 1 after bleomycin instillation for the preventive treatment or at day 7 for the therapeutic treatment. Bleomycin caused a maximal reduction of body weight at day 7 with a subsequent recovery phase. With preventive as well as therapeutic olodaterol treatment, the recovery back to control levels of body weight (at day 21) was accelerated ( Figure 6A ). On day 21, total cell counts were significantly increased in the BALF of mice stimulated with bleomycin ( Figure 6B ). The most prominent increase in cell number was found for lymphocytes and monocytic cells. The influx of white blood cells into the lung was significantly attenuated by olodaterol, by approximately 30%, in both treatment regimens. For lymphocytes, only the preventive treatment showed significant inhibitory effects, whereas in the therapeutic treatment regimen, we only observed a trend towards inhibition. For Data are mean values ± SEM from n = 3 HLF donors and n = 5 IPF-LF donors. Densitometric evaluation of phospho-proteins was normalized to loading control (GAPDH). Values are expressed as % inhibition of FGF-stimulated effect. *P < 0.05, significantly different from FGF-treated cells; ANOVA followed by Fisher's LSD test for parametric data: ns, not significant.
Figure 6
Olodaterol attenuates bleomycin-induced lung fibrosis in mice. C57BL/6 mice received an intratracheal instillation of NaCl (Ctr, n = 18) or 0.5 mg·kg À1 bleomycin (Blm, n = 24). Olodaterol was administered each day by inhalation (1 mg·mL À1 ) either in a preventive regimen from day 1 to 20 (Prev, n = 12) or in a therapeutic mode from day 7 to 20 (Ther, n = 24). Analyses were performed at day 21. Body weight is expressed as % of starting weight (A). Cell count is expressed as total cell count per lung; WBC, white blood cells (B). Lung density was measured by μCT analysis (C). Ashcroft scoring was performed according to Ashcroft et al. (1988) (D) . FVC was measured with flexiVent (E). Lungs were weighed before lavage. Relative lung weights are expressed as % of body weight (F). Total protein concentration in BALF was determined with a BCA assay (G). Col1A1 gene expression in lung was determined via qRT-PCR (H). Expression of β 2 -adrenoceptor (β2-AR) protein expression was determined by ELISA (I). Representative μCT pictures of mouse lungs (J). Representative images from mouse lungs (formalin-fixed, paraffin embedded); Masson trichrome staining; 2.5× (K). Data shown are means ± SEM. *P < 0.05, significantly different as indicated. Bleomycin-treated groups were compared with untreated groups, with unpaired Student's t-test. Olodaterol-treated groups were compared with Bleomycin-treated control animals, by one-way ANOVA followed by Fisher's LSD test for parametric data.
Olodaterol shows anti-fibrotic efficacy BJP monocytes, only trends in the attenuation of the bleomycininduced effects were seen with both treatment strategies ( Figure 6B ). Regarding alterations in tissue density, bleomycin administration caused a twofold increase in lung density in treated animals compared to control animals, as measured by μCT analysis. Olodaterol treatment starting at day 1 attenuated the increase in lung density non-significantly by approximately 60%. The therapeutic treatment regimen had no effect on this parameter ( Figure 6C ). Regarding the bleomycin-induced increase of the Ashcroft score, olodaterol Figure 6 (Continued) Table 2 Analysis of BALF and tissue homogenate for pro-fibrotic and pro-inflammatory mediators in the bleomycin model IL-1β 53 ± 6.3* 213 ± 33.9 124 ± 13.7* 78 ± 18.0* Bleomycin-treated groups were compared with untreated groups by Student's unpaired t-test. Olodaterol-treated groups (n = 10-24 animals per group) were compared with bleomycin-treated animals by one-way ANOVA followed by Fisher's LSD test for parametric data. Values are presented as mean ± SEM *P < 0.05, significantly different from bleomycin-treated animals: ns, not significant.
only showed a trend towards inhibition (by 17%) with preventive, but not with therapeutic, treatment ( Figure 6D ). Figure 6J , K show representative images of the μCT analysis and Masson's trichrome stained lung slices. With respect to lung function parameters, instillation of bleomycin increased lung resistance (Ra) and decreased dynamic lung compliance
Figure 7
Olodaterol attenuates TGF-β-induced lung fibrosis in mice. C57BL/6 mice received an intratracheal instillation of 2.5 × 10 11 vg virus (TGF-β, n = 8)
or PBS (Ctr, n = 8). Olodaterol was administered each day by inhalation (1 mg·mL À1 ) either in a preventive regimen from day 1 to 20 (Prev, n = 8) or in a therapeutic mode from day 7 to 20 (Ther, n = 8). Analyses were performed at day 21. Body weight is expressed as % of starting weight (A). Cell count is expressed as total cell count per lung; WBC, white blood cells; M, monocytic cells; L, lymphocytes; N, neutrophils (B). Lung density was measured by μCT analysis (C). FVC was measured with flexiVent (D). Lungs were weighed before lavage. Relative lung weights are expressed as % of body weight (E). Total protein concentration in BALF was determined with a BCA assay (F). Col3A1 gene expression in lung was determined via qRT-PCR (G). Representative μCT pictures of mouse lungs (H). Data shown are means ± SEM. *P < 0.05, significantly different as indicated. AAV6.2m-TGF-β1-treated groups were compared with untreated groups, with unpaired Student's t-test. Olodaterol-treated groups were compared with AAV6.2m-TGF-β1-treated control animals, by one-way ANOVA followed by Fisher's LSD test for parametric data.
(Cdyn) and forced vital capacity (FVC), compared with control animals. Preventive olodaterol treatment inhibited the FVC decline significantly, by 45% ( Figure 6E ). These trends were also seen for the attenuation of the increase in resistance and the reduction in lung compliance by 57 and 71% respectively (data not shown). Other parameters such as the increase in relative lung weight (1.5-fold) and the total protein content in BALF (9.3-fold) were also significantly reduced in the preventive, as well as the therapeutic, treatment with olodaterol (33 and 43%, respectively) ( Figure 6F, G) . Furthermore, the fibrosis-relevant mediators, MMP-9, TGF-β and TIMP-1, were increased in BALF of bleomycin-treated animals (4.3-fold, 5.6-fold and 35.3-fold, respectively) and were significantly inhibited by olodaterol inhalation by about 50 to 70%, regardless of treatment start (Table 2) . Other mediators, such as KC, TNF-α, IL-6, IFN-γ and IL-1β, were also significantly induced in bleomycin-treated animals. With exception of IL-6 and IFNγ, olodaterol reduced these mediators by about 60 to 80% (Table 2) . Furthermore, bleomycin induced a 4.3-fold increase of collagen I (Col1A1) mRNA in the lungs. This increase was inhibited, albeit not significantly, by olodaterol by 21 and 34% with therapeutic and preventive treatment respectively ( Figure 6H ). Expression of β 2 -adrenoceptor protein in lung homogenates was reduced after bleomycin challenge ( Figure 6I ). No significant changes in levels of β 2 -adrenoceptors were observed with olodaterol treatment.
Olodaterol attenuates pro-fibrotic mechanism in a murine model of TGF-β1-induced lung fibrosis
To confirm the efficacy of olodaterol on TGF-β-induced mechanisms, we used a mechanistic mouse model of AAV6.2m-TGF-β1-induced lung fibrosis. Olodaterol treatment was performed according to the treatment regimen in the bleomycin study. Overexpression of TGF-β1 in mouse lungs caused a reduction in body weight by 5 -10%, from day 10 to 21 after virus instillation. This weight loss was inhibited by olodaterol with both preventive and therapeutic treatment ( Figure 7A ). Furthermore, TGF-β1-overexpression induced a significant extravasation of immune cells into the lungs as measured in BALF ( Figure 7B ). Challenge with AAV6.2m-TGF-β1 caused an increase in lymphocyte, neutrophil and monocytic cell counts. Preventive olodaterol treatment significantly attenuated the influx of monocytes and lymphocytes by about 40%, whereas therapeutic treatment only resulted in 20% inhibition. Neutrophil numbers in BALF were reduced by 43% with preventive treatment, but non-significantly increased with the therapeutic regimen ( Figure 7B ). With regard to fibrotic remodelling, AAV6.2m-TGF-β1 instillation resulted in a fourfold increase in lung density as measured by μCT. Therapeutic olodaterol treatment had no effect on the increase in tissue density, although preventive treatment resulted in 36% inhibition ( Figure 7C ). Figure 7H shows representative images of the μCT analysis. These TGF-β1-induced changes in lung parameters altered functional parameters, as the FVC decreased in AAV6.2m-TGF-β1-treated mice. However, olodaterol treatment did not show significant effects on this decline of FVC ( Figure 7D ). Furthermore, AAV6.2m-TGF-β1 treatment induced an increase in relative lung weight and protein content in BALF. With preventive treatment, olodaterol attenuated the increase in lung weight and BALF protein by over 50%. Further, therapeutic treatment caused a decrease of about one third in both parameters ( Figure 7E, F) . TGF-β overexpression also resulted in a 4.5-fold increase of collagen III mRNA (Col3A1). This increase was significantly inhibited by 37 and 50% with therapeutic and preventive treatment respectively ( Figure 7G ). Furthermore, AAV6.2m-TGF-β1 instillation caused an increase in MMP9, TGF-β and TIMP-1 in BALF. Preventive treatment again attenuated this mediator release significantly up to 70%, while therapeutic treatment had no inhibitory effect (Table 3) .
Discussion and conclusions
Olodaterol (Striverdi®) is a long-acting β 2 -adrenoceptor agonist marketed as a bronchodilator for the maintenance treatment of COPD (Bouyssou et al., 2010b) . Besides its wellproven bronchodilatory activity, olodaterol has recently been demonstrated to elicit anti-inflammatory activity in mouse models of cigarette smoke and lipopolysaccharide-induced lung inflammation and to have anti-tussive properties in guinea pigs (Wex and Bouyssou, 2015) . However, its anti-fibrotic activity has not been systematically evaluated. Thus, the objective of our study was to test the efficacy .2m-TGF-β1-treated groups were compared with untreated groups by an unpaired Student's t-test. Olodaterol-treated groups (n = 8 animals per group) were compared with AAV6.2m-TGF-β1-treated animals by one-way ANOVA followed by Fisher's LSD test for parametric data. Data shown are means ± SEM. *P < 0.05, significantly different from animals treated with AAV6.2m-TGF-β1; ns, not significant.
of the long-acting β 2 -adrenoceptor agonist olodaterol to inhibit pro-fibrotic mechanisms in primary HLF from control donors and IPF patients and to evaluate whether our findings translate into the in vivo situation. In a first set of experiments, we demonstrated that olodaterol stimulates cAMP release in HLF from control and IPF donors in a β 2 -adrenoceptor-dependent manner. Some differences were seen regarding the maximal cAMP release in HLF and IPF-LF, but these results were not significantly different. Furthermore, the EC 50 values of intracellular cAMP increase after olodaterol stimulation was in good agreement with the EC 50 values determined in CHO cells (Bouyssou et al., 2010a) .
With TGF-β being one of the major activators of the transition of fibroblasts to myofibroblasts, many treatments aim to inhibit TGF-β-induced signalling pathways. Our data demonstrate that olodaterol blocks the TGF-β-induced fibroblastto-myofibroblast differentiation in both HLF and IPF-LF, as indicated by the inhibition of α-SMA protein expression, as well as the attenuated release of fibronectin, PICP (a surrogate marker reflecting type I collagen synthesis) and the profibrotic mediator ET-1. These findings are in good agreement with an abstract by Wang et al. (2012) , showing the inhibitory effects of olodaterol on collagen synthesis by human fibroblasts. Additionally, indacaterol and isoprenaline were shown to inhibit TGF-β-induced pro-fibrotic protein expression in normal human lung and cardiac fibroblasts (Liu et al., 2006; Tannheimer et al., 2012) . In another functional bioassay, the gel contraction assay, olodaterol, inhibited the TGF-β plus ET-1-stimulated contraction of HLF and, to a lesser extent, of IPF-LF. In accordance with our findings, Schiller et al. (2010) showed inhibitory effects of db-cAMP (a stable cAMP analogue) on TGF-β-induced contraction of NIH3T3 cells. However, the exact mechanism of how cAMP interferes with the TGF-β signalling cascade is unclear. One possible explanation is the interference of cAMP with TGF-β-specific Smad3/4-dependent gene expression. The sequestration of the transcriptional co-activators CBP and p300 by phospho-CREB would make them unavailable for recruitment to Smad transcriptional complexes (Schiller et al., 2010) . Additionally, cAMP may further oppose fibrotic responses via the PKA or Epac-mediated inhibition of TGF-β stimulated ERK1/2 and JNK activation (Liu et al., 2006) . Nevertheless, the final clarification of the pivotal mechanism in the inhibition of TGF-β-mediated signalling will need further exploration.
Besides TGF-β, additional mediators are found to be elevated in fibrotic tissues, such as PDGF, FGF or EGF (Bonner, 2004; Hetzel et al., 2005; Wollin et al., 2014) . They are believed to play important roles in the pathogenesis of IPF by stimulating fibroblast survival, proliferation and migration. Thus, reducing fibroblast proliferation and migration in IPF will reduce spreading and accumulation of myofibroblasts. In this study, we demonstrated that olodaterol inhibits the growth factor-induced motility and proliferation of human primary lung fibroblasts with significantly different potency in HLF compared to IPF-LF. Accordingly, other β 2 -adrenoceptor agonists like isoprenaline or formoterol were shown to inhibit proliferation and migration upon FGF-and PDGF-stimulation in different cell lines (Chen et al., 2008; Lamyel et al., 2011) . There are several studies suggesting a link between cAMP-dependent PKA activation and cellular migration (Howe, 2004; Chen et al., 2008) . Furthermore, various articles show an inhibition of cell proliferation by cAMP elevating agents, in a PKA or Epac-1 dependent manner (Hafner et al., 1994; Stork and Schmitt, 2002; Huang et al., 2008) .
To evaluate the inhibitory activity of olodaterol on relevant kinases, activated by pro-fibrotic growth-factors, we performed Western blot analysis after FGF stimulation. Our results show distinct inhibitory effects of olodaterol on FGFinduced Akt, c-Raf and JNK phosphorylation, while the phosphorylation of other kinases like p38 or ERK1/2 was only attenuated or unaffected (PLCγ).
Summarizing the in vitro part of our data, we found no significant differences regarding the efficacy of olodaterol in inhibiting pro-fibrotic mechanisms in HLF compared to IPF-LF. This indicates that β 2 -adrenoceptors are still functional in cells from fibrotic patients and builds a rationale for the efficacy of olodaterol in IPF. The effects of olodaterol in healthy cells is not a matter of concern to us, with regard to altered wound healing, as olodaterol has been used in clinical practice for several years without showing detrimental effects on physiological wound healing processes. Additionally, further research will be needed to elucidate how olodaterol interferes with signal cascades, activated by other growth factors, and whether this interference is stimulus-, cell-and/or disease status-dependent. Moreover, it will be necessary to identify the anti-fibrotic effects of olodaterol in other fibrosis relevant cell types, such as epithelial cells (mediator release and EMT) or macrophages (mediator release, migration and differentiation).
Having shown the efficacy of olodaterol to inhibit profibrotic mechanisms in several disease-relevant functional fibroblast assays, we explored whether these effects translated into in vivo efficacy. With regard to the dosing, we based our dose estimation for the fibrosis models on functional data generated in a model of acetylcholine-induced bronchoconstriction . In this model, a concentration of 1 mg·mL À1 olodaterol given by inhalation was determined as the first dose showing maximal bronchodilation. Therefore, we used the same experimental set-up with regard to the olodaterol inhalation in our fibrosis models.
In the bleomycin-induced lung fibrosis model, intratracheal instillation of bleomycin results in an initial lung injury, followed by an inflammatory response and the subsequent development of fibrosis. Even though this model shows some limitations regarding the transferability to human IPF, it is still a good tool to assess efficacy of potential compounds in general as proof of principle (Moeller et al., 2008) . We show that weight loss induced by bleomycin challenge was diminished with olodaterol treatment in both treatment regimens. Furthermore, in line with its antiinflammatory efficacy, olodaterol reduced the pulmonary influx of white blood cells into the lung and attenuated the levels of pro-inflammatory and pro-fibrotic mediators in BALF. These data demonstrate an additional dimension of the inhibitory effects of olodaterol. In contrast to our in vitro assays, not only the inhibition of mediator-induced effects, but also the release of those pro-fibrotic mediators and the influx of disease-relevant cell types (for example macrophages) can be investigated in vivo. Furthermore, preventive treatment also attenuated the decline in FVC and showed trends towards an inhibition of the increase in lung density (the two main parameters used in the diagnosis of IPF in the clinical situation) and collagen I deposition. However, with therapeutic treatment, no significant effects on lung density or Ashcroft score were seen.
To confirm our results from the bleomycin model and to further dissect effects of olodaterol on inflammation and direct anti-fibrotic effects, we chose to test olodaterol in another, more mechanistic, lung fibrosis model. For this purpose, we chose an AVV6.2-TGF-β1 overexpression model. Compared to the common adenovirus-5 technique, no measurable inflammation after transduction with the AAV6.2 is present, and thus, the model has a lower risk to misinterpret anti-fibrotic findings due to an anti-inflammatory mechanism of a drug. Lung epithelial cells secrete large amounts of TGF-β after being transduced by AAV6.2-TGF-β1. This overexpression of TGF-β results in fibrotic conditions as determined by a decrease in FVC and an increase in lung density without an initial inflammatory phase (Strobel et al., 2015) . In this model, preventive olodaterol treatment significantly reduced lung density (as determined by μCT analysis), Col3A1 mRNA expression and the release of pro-fibrotic mediators. With the early inflammation phase being absent in this model, the inhibitory effects of olodaterol given in a preventive manner are interfering with TGF-β-driven mechanisms and cannot be attributed to the anti-inflammatory properties of the compound.
In summary, our in vivo experiments support anti-fibrotic actions of olodaterol both, in the bleomycin model, as well as in a model of TGFß-induced fibrosis. In both models, the most prominent effects were seen with a preventive dosing regimen compared to the therapeutic approach. As fibrosis in IPF is often described as being 'patchy' in its distribution with intervening areas of unaffected lung, a preventive approach confining disease progression by inhibiting fibroblast activation at early stages might attenuate spreading of fibrotic regions (King et al., 2011) .
Having seen trends towards a reduced efficacy of olodaterol to inhibit pro-fibrotic mechanisms in IPF compared to healthy fibroblasts, we investigated the β 2 -adrenoceptor expression in cell lysates and in lung homogenate after bleomycin challenge. Protein expression analysis of cell lysates revealed comparable expression levels of the β 2 -adrenoceptor in HLF and IPF fibroblasts. However, we found reduced β 2 -adrenoceptor protein expression in bleomycin-challenged mice. With this observation in mind, we checked the expression of β 2 -adrenoceptors in other data sets. Our in-house next-generation sequencing (NGS) data of murine bleomycin models, the mouse AAV6.2m-TGF-β1 overexpression model and TGF-β-treated primary HLF and the analysis of external NGS studies (GSE1066; Konishi et al., 2009; GSE52463; Nance et al., 2014) together with current and earlier literature (Giri et al., 1987; Bauer et al., 2015) revealed a general down-regulation of β 2 -adrenoceptors in IPF lung samples and IPF-related in vitro and in vivo models. This is in contrast to our observation that, in vitro, cultures of IPF-LF and HLF showed no significant differences in expression of β 2 -adrenoceptors. It is possible that the absence of differences in β 2 -adrenoceptor protein between healthy and IPF fibroblasts might be caused by an assimilation of the receptor expression due to the in vitro culture of the primary cells on hard plastic dishes and in standardized culture media. However, this will need further investigation. Additionally, besides the levels of β 2 -adrenoceptors, other proteins involved in the downstream signalling of the β 2 -adrenoceptor, such as PDE-4, might also be differentially expressed and thereby might influence the responsiveness of IPF-LF to cAMP-increasing drugs. However, to evaluate the validity of this hypothesis, additional experiments need to be done. Whether other cAMPelevating agents (not relying on β 2 -adrenoceptors) show more pronounced inhibitory effects in fibrotic in vitro and in vivo models will also need further investigation.
Taken together, our in vitro data demonstrated that olodaterol attenuated pro-fibrotic mechanisms involved in the onset and progression of IPF, including the proliferation, trans-differentiation, migration, contraction, ECM production and pro-fibrotic mediator release of primary HLF. In a mechanistic TGF-β-driven fibrosis model in mice, we demonstrated that olodaterol significantly attenuated the increase in lung density, Col3A1 mRNA expression and the release of pro-fibrotic mediators when given preventively. Likewise, olodaterol attenuated the FVC decline and reduced the release of pro-fibrotic mediators in a model of bleomycininduced lung fibrosis when given in a prophylactic manner. Our data provided clear evidence that stimulation of the β 2 -adrenoceptor attenuates pro-fibrotic events both in healthy and diseased settings and, thus, supports the hypothesis that cAMP-increasing drugs might be beneficial in the treatment of IPF. As IPF is known to be a heterogeneous disease, with alternating preserved and fibrotic areas, a preventive treatment and effects on non-diseased cells might inhibit the transition of normal to fibrotic lung fibroblasts and thus halt disease progression in yet unaffected regions. However, due to the possible down-regulation of the β 2 -adrenoceptor under fibrotic conditions, it might be assumed that cAMP-elevating mechanisms independent of the β 2 -adrenoceptor could be an even more effective choice in clinical conditions. Whether the robust inhibition of pro-fibrotic mechanisms in HLF or the weaker anti-fibrotic activity demonstrated only in the preventive treatment regimen in animal models of lung fibrosis is the better predictor of effective translation to a clinical treatment option is still an open question. the manuscript. J.W. performed the immunocytochemistry. B.L. performed the NGS analyses. All authors contributed to scientific discussions and approved the manuscript.
